Mkt Cap$2.12T-2.21%
24h Vol$76.93B
BTC Dom55.4%
ETH Dom8.9%
F&G15Extreme Fear
BTC$58,525.00-2.87% ETH$1,566.72-2.66% USDT$0.9985-0.02% USDC$0.9996-0.01% BNB$544.90-2.56% XRP$1.04-1.83% SOL$73.31-2.61% TRX$0.315-1.87% FIGR_HELOC$1.01-3.51% HYPE$64.60-3.63% DOGE$0.0718-2.19% RAIN$0.0157-1.31% USDS$0.9995-0.01% LEO$9.26-3.16% ZEC$394.57-3.26% WBT$53.93+12.53% BTC$58,525.00-2.87% ETH$1,566.72-2.66% USDT$0.9985-0.02% USDC$0.9996-0.01% BNB$544.90-2.56% XRP$1.04-1.83% SOL$73.31-2.61% TRX$0.315-1.87% FIGR_HELOC$1.01-3.51% HYPE$64.60-3.63% DOGE$0.0718-2.19% RAIN$0.0157-1.31% USDS$0.9995-0.01% LEO$9.26-3.16% ZEC$394.57-3.26% WBT$53.93+12.53%
News

VNDA

Total Stories
2
Section
VNDA
Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug
Market Analysis

Vanda (VNDA) Stock Skyrockets on FDA Approval for Bipolar, Schizophrenia Drug

Vanda stock jumped more than 40% in premarket trading after the FDA approved its new drug BYSANTI for Bipolar I disorder and schizophrenia.

Tim FriesFeb 23, 20263 min read